SHARED CONDITION LIBRARY

Respiratory Conditions (other than tuberculosis and sleep apnea)

This reference covers Asthma, Chronic obstructive pulmonary disease. Use the examination topics below to find the relevant evidence.

Clinical references and scope

Asthma — diagnostic reference

Partial diagnostic criteria

Adults; asthma only

GINA 2026 strategy report and summary guide

Symptoms and airflow variability

Compatible variable respiratory symptoms plus evidence of variable expiratory airflow limitation.

Frequently Asked Questions ↗ · How is asthma diagnosed?

Objective assessment

Spirometry with bronchodilator comparison, peak-flow assessment or selected challenge testing supports evaluation; FeNO assesses airway inflammation.

Asthma: Diagnosis ↗ · Diagnostic tests

Adult bronchodilator response

With compatible variable symptoms: FEV1 or FVC increase ≥12% AND ≥200 mL from baseline; PEF increase ≥20% is an alternative when spirometry is unavailable.

2026 GINA Summary Guide ↗ · Table 1, p. 8; pp. 9–10

Other objective variability routes

Adult routes include average daily PEF variability >10% across two weeks; four-week ICS response ≥12% and ≥200 mL in FEV1 or FVC; or between-visit FEV1 change ≥12% and ≥200 mL. PEF alternatives use ≥20%. Standardized bronchial challenge is another route.

2026 GINA Summary Guide ↗ · Table 1, p. 8; pp. 9–10

Testing and differential context

Apply source-specific measurement protocols; PEF is less reliable. Negative testing can require reassessment during symptoms. Biomarkers support Type 2 asthma but neither establish asthma alone nor exclude it when low. Consider COPD, cardiac disease and cough mimics; treated patients need a separate confirmation pathway.

2026 GINA Summary Guide ↗ · Table 1, p. 8; pp. 9–10

Confirmation after inhaled corticosteroids

Treatment can suppress airflow variability. Review earlier spirometry and the timing of inhalers. If symptoms persist, repeat testing during symptoms or after a clinician-directed bronchodilator hold appropriate to the drug.

Global Strategy for Asthma Management and Prevention ↗ · Boxes 1-4 and 1-5, diagnostic confirmation during ICS treatment

When initial testing is inconclusive

For few symptoms and lung function above 70% predicted, the clinician may supervise a treatment reduction with a written action plan and repeat testing in 2–4 weeks. With frequent symptoms and lung function below 70% predicted, the clinician may increase treatment and reassess in 1–2 months. Persistent uncertainty warrants specialist evaluation.

Global Strategy for Asthma Management and Prevention ↗ · Boxes 1-4 and 1-5, diagnostic confirmation during ICS treatment
2026 GINA Summary Guide ↗ · How to confirm the diagnosis of asthma in patients taking ICS, p. 9

Adult challenge results

Interpret the fall in FEV1 against the challenge used. Methacholine uses at least 20%. Standardized mannitol, hypertonic saline or hyperventilation uses at least 15%. With standardized exercise, both a fall greater than 10% and a drop greater than 200 mL are required. The laboratory checks test quality and clinical suitability.

Global Strategy for Asthma Management and Prevention ↗ · Box 1-2, adult bronchial provocation

Clues to another cause

Inspiratory noise during exertion suggests inducible laryngeal obstruction. Daily sputum or recurrent infection warrants evaluation for bronchiectasis. Breathlessness when lying flat or ankle swelling supports cardiac assessment. In a person with smoking or occupational exposure, evaluate persistent airflow obstruction for COPD.

Global Strategy for Asthma Management and Prevention ↗ · Box 1-3, differential diagnosis in adults

Challenge test safety

The laboratory screens baseline lung function, ability to repeat spirometry and cardiovascular risks. ERS advises against incremental challenge with adult pre-test FEV1 below 60% predicted or below 1.5 L. Exercise and voluntary hyperpnoea challenge use a 75%-predicted safety boundary. Refer recent stroke or myocardial infarction, uncontrolled hypertension and other contraindications to the supervising clinician.

Technical standard for methacholine challenge testing ↗ · Table 1, Contraindications; Patient safety; test procedure step 11

Supervision and recovery

A trained team must be ready to reverse bronchoconstriction and respond to an emergency. At the protocol endpoint, stop the challenge, give the rescue bronchodilator and repeat spirometry to document recovery before discharge. The testing laboratory sets agent-specific dosing, medication holds and discharge criteria.

Technical standard for methacholine challenge testing ↗ · Table 1, Contraindications; Patient safety; test procedure step 11

Testing during pregnancy

Use symptom history and available objective airflow measurements. Bronchial provocation is contraindicated during pregnancy. Avoid reducing inhaled corticosteroid treatment merely to demonstrate variability. If the history supports asthma and objective confirmation is still needed, maintain clinician-directed care and arrange confirmation after delivery.

Global Strategy for Asthma Management and Prevention ↗ · Chapter 1, Confirming the diagnosis in specific populations: pregnant women

Severe asthma work-up

First verify the diagnosis, inhaler technique, adherence, exposures and comorbidities. In severe asthma on high-dose inhaled treatment, evidence of Type 2 inflammation can include blood eosinophils ≥150/µL, exhaled nitric oxide ≥20 ppb, sputum eosinophils ≥2%, or a convincing allergen-driven pattern. Oral corticosteroids may suppress biomarkers. A specialist can repeat measurements up to three times, preferably before a course or at least one to two weeks afterward, or on the lowest feasible dose. Biologic eligibility requires separate criteria.

Difficult-to-Treat and Severe Asthma ↗ · Figure 3 and sections 5–7, investigation and assessment of phenotype

Scope of this clinical reference

  • The specialist laboratory determines individual contraindications, dosing and recovery. Local biologic eligibility and pregnancy-specific care require clinical review.
Frequently Asked Questions ↗ · How is asthma diagnosed?
Asthma: Diagnosis ↗ · Diagnostic tests
Global Strategy for Asthma Management and Prevention ↗ · Boxes 1-4 and 1-5, diagnostic confirmation during ICS treatment · Box 1-2, adult bronchial provocation · Box 1-3, differential diagnosis in adults · Chapter 1, Confirming the diagnosis in specific populations: pregnant women
Technical standard for methacholine challenge testing ↗ · Table 1, Contraindications; Patient safety; test procedure step 11
Difficult-to-Treat and Severe Asthma ↗ · Figure 3 and sections 5–7, investigation and assessment of phenotype

Chronic obstructive pulmonary disease

Partial diagnostic criteria

COPD only; asthma and other lung conditions require their own frameworks.

GOLD 2026 strategy report and NHLBI

Clinical evaluation

Symptoms and exposure risks guide evaluation for chronic airflow disease.

Chronic obstructive pulmonary disease — source ↗ · Lung function tests; Other tests
Global Strategy for Prevention, Diagnosis and Management of COPD ↗ · Chapter 2, Spirometry and Diagnostic criterion for airflow obstruction, pp. 28–31 · Chapter 2, Differential diagnosis of COPD · Chapter 2, Initial assessment: airflow obstruction, symptoms and exacerbation history

Assessment methods

Spirometry is the principal test; imaging and blood-gas testing may address additional clinical questions.

Chronic obstructive pulmonary disease — source ↗ · Lung function tests; Other tests
Global Strategy for Prevention, Diagnosis and Management of COPD ↗ · Chapter 2, Spirometry and Diagnostic criterion for airflow obstruction, pp. 28–31 · Chapter 2, Differential diagnosis of COPD · Chapter 2, Initial assessment: airflow obstruction, symptoms and exacerbation history

Interpretation and scope

No single symptom or imaging abnormality is substituted for the clinical and physiological evaluation.

Chronic obstructive pulmonary disease — source ↗ · Lung function tests; Other tests
Global Strategy for Prevention, Diagnosis and Management of COPD ↗ · Chapter 2, Spirometry and Diagnostic criterion for airflow obstruction, pp. 28–31 · Chapter 2, Differential diagnosis of COPD · Chapter 2, Initial assessment: airflow obstruction, symptoms and exacerbation history

Confirming persistent obstruction

In someone with compatible symptoms or exposures, measure FEV1 and FVC after a bronchodilator. A ratio below 0.70 supports persistent obstruction. Record acceptable, repeatable efforts and consider alternative causes before attributing obstruction to COPD.

Global Strategy for Prevention, Diagnosis and Management of COPD ↗ · Chapter 2, Spirometry and Diagnostic criterion for airflow obstruction, pp. 28–31

Results near the cutoff

Repeat spirometry on another occasion when the post-bronchodilator ratio is between 0.60 and 0.80. Biological variation can move the result across the cutoff. The fixed ratio can classify more older adults and fewer younger adults as obstructed than age-adjusted reference limits.

Global Strategy for Prevention, Diagnosis and Management of COPD ↗ · Chapter 2, Spirometry and Diagnostic criterion for airflow obstruction, pp. 28–31

Interpreting tests during treatment

Record usual inhalers, last doses and whether the test is for confirmation or follow-up. For monitoring established COPD, GOLD allows regular bronchodilators to continue. Use the post-bronchodilator ratio for diagnostic confirmation. The size of the immediate response alone cannot distinguish asthma from COPD.

Global Strategy for Prevention, Diagnosis and Management of COPD ↗ · Chapter 2, Spirometry, considerations when performing spirometry · Chapter 2, Spirometry and Diagnostic criterion for airflow obstruction, pp. 28–31

Other causes of breathlessness and cough

Consider asthma when symptoms vary markedly. Signs of congestion warrant evaluation for heart failure. Recurrent infection and copious sputum raise bronchiectasis as a possibility. Examination, imaging and history guide investigation, including for coexisting conditions.

How COPD affects the person

After confirmation, document FEV1 percent predicted, breathlessness during activities, overall symptom burden, and exacerbations or admissions in the past year. These describe different aspects of COPD and guide follow-up.

Global Strategy for Prevention, Diagnosis and Management of COPD ↗ · Chapter 2, Initial assessment: airflow obstruction, symptoms and exacerbation history

COPD patterns

Persistent productive cough for at least three months in each of two successive years supports chronic bronchitis after other causes are considered. CT can characterize emphysema and identify coexisting bronchiectasis. When symptoms and spirometry disagree, lung volumes, gas transfer or exercise testing can clarify the source of limitation.

Global Strategy for Prevention, Diagnosis and Management of COPD ↗ · Chapters 1–2, Chronic bronchitis, Imaging and Additional investigations

Inherited and inflammatory traits

GOLD recommends testing people with COPD for alpha-1 antitrypsin deficiency, including older adults. Blood eosinophils help estimate the likely preventive benefit of inhaled corticosteroids alongside exacerbation history. A count alone cannot identify the cause of an individual flare.

Global Strategy for Prevention, Diagnosis and Management of COPD ↗ · Chapter 2, Blood eosinophil count and Alpha-1 antitrypsin deficiency

Causes of a flare

Compare the event with baseline. Worsening breathlessness, cough or sputum over up to 14 days supports an exacerbation. Infection and pollution are common triggers. Pneumonia, pulmonary embolism, heart failure and pneumothorax can resemble or accompany a flare. Record the evidence for each plausible contributor and any uncertainty about the cause.

Global Strategy for Prevention, Diagnosis and Management of COPD ↗ · Chapter 4, Definition and diagnosis, Figures 4.2–4.3

Evaluating a flare

Assess oxygenation, respiratory and heart rates, mental status and work of breathing. Select tests from the presentation: chest imaging for consolidation or pneumothorax, ECG and cardiac testing for suspected cardiac disease, and a probability-based embolism work-up when indicated. The examining clinician determines urgency and attribution.

Global Strategy for Prevention, Diagnosis and Management of COPD ↗ · Chapter 4, Definition and diagnosis, Figures 4.2–4.3
Related VA rules and distinctions

Clinical COPD assessment and VA evaluation

GOLD symptom burden and exacerbation history guide clinical care. VA evaluates COPD under DC 6604 using the listed lung-function measures or specified clinical findings. Section 4.96(d) sets testing exceptions and directs the use of post-bronchodilator values unless poorer than the pre-test results. When different measures imply different evaluations, the examiner identifies the measure that best reflects disability. A GOLD stage or symptom score alone supplies no VA percentage.

38 CFR § 4.96 ↗ · (d)(1)–(7)
38 CFR § 4.97 ↗ · Diagnostic code 6604

Scope of this clinical reference

  • Imaging, laboratory findings and competing causes require individual interpretation. An event with multiple plausible causes can remain clinically indeterminate.
Chronic obstructive pulmonary disease — source ↗ · Lung function tests; Other tests
Global Strategy for Prevention, Diagnosis and Management of COPD ↗ · Chapter 2, Spirometry and Diagnostic criterion for airflow obstruction, pp. 28–31 · Chapter 2, Differential diagnosis of COPD · Chapter 2, Initial assessment: airflow obstruction, symptoms and exacerbation history · Chapters 1–2, Chronic bronchitis, Imaging and Additional investigations · Chapter 2, Blood eosinophil count and Alpha-1 antitrypsin deficiency · Chapter 4, Definition and diagnosis, Figures 4.2–4.3

Professional assessments

Evidence and examination topics

  • Diagnosis and history: Records identifying the current diagnosis, onset, course, and relevant medical history.
  • Diagnosis and history: Records identifying the current respiratory diagnosis, diagnosis date, onset, course, and relevant treatment history.
    • Current respiratory diagnosis
    • Diagnosis date
    • Condition onset and course
  • Diagnostic tests and measurements: Condition-relevant tests, imaging, laboratory results, and objective measurements.
  • Pulmonary function tests: Pulmonary function testing or spirometry reports containing measurements relevant to asthma evaluation.
    • Test date
    • FEV-1 percent predicted
    • FEV-1/FVC ratio
    • Pre- or post-bronchodilator context
    • Examiner interpretation
  • Functional impact: Medical and lay evidence describing work and daily-activity effects.
  • Clinical findings: Examination findings that are relevant to the public DBQ or rating criteria.
  • Treatment and medications: Medication lists, prescriptions, pharmacy records, and treatment notes describing asthma therapy and frequency of use.
    • Bronchodilator therapy and frequency
    • Inhaled anti-inflammatory therapy
    • Systemic corticosteroid courses
    • Daily high-dose systemic therapy
  • Symptoms and episodes: Records or statements documenting symptoms, severity, frequency, duration, and episodes.
  • Treatment and medications: Treatment records, medication history, procedures, and therapy documentation.
  • Service connection evidence: Evidence addressing an in-service event, exposure, disease, injury, continuity, or a secondary relationship.
  • Exacerbations and physician visits: Treatment records documenting asthma attacks, respiratory failure, exacerbations, emergency care, and required physician visits.
    • Asthma attacks with respiratory failure
    • Physician visits for exacerbations
    • Start of the documented 12-month period
  • Service event and exposure: Service records and lay or medical evidence describing onset, relevant duties, respiratory events, or qualifying exposures during service.
    • In-service event, disease, symptoms, or exposure
    • Service event or exposure date range
  • Medical connection evidence: Medical opinions and supporting records addressing a relationship between the current asthma condition and service or another service-connected condition.
    • Medical connection opinion
    • Supporting medical rationale

What the VA questionnaire covers

Official Respiratory Conditions (other than tuberculosis and sleep apnea) questionnaire ↗

Source version 24_2; updated 2024-08-27. Use the original questionnaire for the complete wording and exceptions.

  • diagnosis · source pages 1, 2
  • medical history · source pages 3, 4
  • pulmonary conditions · source pages 4, 5, 6, 7, 8, 9
  • diagnostic testing · source pages 9, 10, 11
  • functional impact · source pages 11
  • remarks · source pages 11

Full rating rules and tables

Understand service-connection and nexus evidence →

Related rating guides

Shared reference edition 1.2.4 · source check 2026-11-06. Coverage is stated for each framework and is distinct from clinical review. Rating-source snapshot: 2026-06-30.

About these educational tools

The calculator and guides provide general education, not medical, legal, or financial advice. Using them does not create a clinician-patient, evaluator-evaluee, or attorney-client relationship. Professional services require a separate accepted engagement.

VA determines eligibility, service connection, ratings, qualifying dependents, effective dates, and the amount payable. Using these tools does not submit a claim or appeal.

Diagnosis, connection to service, and severity are separate questions. Matching a description or screening score does not establish a diagnosis or entitlement. A qualified clinician should interpret medical findings. Do not change treatment based on these guides.

Ingleside Health is an independent physician service, not a law firm or VA-accredited claims representative. It is not affiliated with or endorsed by VA and does not prepare, present, prosecute, or file benefits claims.

Do not rely on an estimate alone for financial commitments or claim decisions. Check official VA information and seek appropriate individual advice.

Calculation assumptions and exclusions
  • Basic compensation estimate. Special Monthly Compensation (SMC), Total Disability based on Individual Unemployability (TDIU), offsets or recoupment, back pay, temporary total ratings, and unsupported adult-dependent categories are not calculated.
  • Bilateral handling covers the supported arm/leg selections. Other paired skeletal muscles, amputation limits, and overlapping manifestations need individual review. The tool cannot determine whether every entered rating may be separately combined.
  • Use separately established evaluations or clearly hypothetical percentages. Choosing a condition or percentage does not establish diagnosis, service connection, or entitlement.
  • Uses 2026 compensation rates effective December 1, 2025. Historical payments, future rate changes, and individual effective dates are not calculated. See the source dates on each reference; rules and rates may change.
Using the website or a chat tool

Calculator selections stay in this browser tab's memory and are not saved or submitted as intake. Refreshing the page resets the example. Do not enter personal records or identifiers. Website visits remain subject to the Website Privacy Policy.

Use hypothetical scenarios only in chat tools. Do not send records, identifiers, symptoms, or real case information. The chat provider's own terms and privacy settings apply; a chat conversation is not the Box-hosted clinical intake.

Accredited Veterans Service Organization (VSO) representatives provide free help with VA benefit claims. Find VA-accredited help. Read VA’s official rating guidance.

Terms of UseWebsite Privacy PolicyAccessibility and help

This business is not endorsed or sponsored by, or affiliated with, the United States Department of Veterans Affairs or the Illinois Department of Veterans Affairs, or any federally chartered VA accredited veteran service organization. You may qualify for other veterans benefits beyond the benefits for which you are receiving services here.

Veteran and military benefits services are available free of charge from VA accredited county veteran service officers, representatives of the Illinois Department of Veterans Affairs, and the veteran service officers of federally chartered veteran service organizations. To learn more, contact these organizations or the Illinois Attorney General's Office at 1-800-382-3000.